Quick Awareness Points for GPs

• Early Value Assessment (EVA) = promising tech with developing evidence

• Allows early NHS access while real-world data is collected

• Not yet full “standard of care”

• Clinical judgement still paramount

• Adverse events → report via MHRA Yellow Card

• COPDPredict removed (company no longer trading)

• Likely implementation via ICB / commissioned COPD pathways

Technology	Status	GP Awareness Note
myCOPD	Included	Previously MTG68
Lenus COPD Support Service	Included	Previously MIB300
COPDPredict	Removed	Not available in NHS

Area	Current Position	Practical Meaning
Evidence maturity	Early / evolving	Use cautiously
Outcomes	Evidence gaps identified	Data collection ongoing
Adoption	Conditional	Likely locally commissioned

These are supported digital tools under evaluation, not mandatory COPD management.
Consider only if locally available and clinically appropriate.

Reference -https://www.nice.org.uk/guidance/htg736